$Reviva Pharmaceuticals Holdings, Inc.(RVPH)$ 📈 🅱️ U Ł Ł ł $ Ҥ🔺
$RVPH: Reviva Pharma Looking Ready to Rebound 🚀
Key Catalyst:
Reviva Pharmaceuticals ($RVPH) recently reported positive Phase 3 data for brilaroxazine in schizophrenia, showing:
• Sustained efficacy 📈
• Strong safety profile 🔒
• High patient adherence over a year
This is a major step toward addressing unmet needs in mental health, a space demanding innovation.
The Offering?
💡 No surprises here. Their last offering on August 21 saw the share price dip before rebounding hard. History may repeat, and dips now could be prime opportunities. I believe RVPH runs past $5 before the end of the year as management focuses on finishing the final Phase 3 FDA requirements.
💰 Valuation:
Ultra-cheap compared to peers like $KRTX’s $12B+ buyout. This pricing undervalues RVPH’s potential pipeline.
Fun Fact:
Brilaroxazine isn’t just tackling schizophrenia. It’s positioned to address CNS diseases, bipolar disorder, and even respiratory conditions like pulmonary hypertension.
Look for dips now. With chatter about buyouts and M&A heating up under a new administration, this could get exciting in 2025!
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Not really interested in these pharmacy sector
Great article, would you like to share it?
Great article, would you like to share it?
Great article, would you like to share it?